ProQR Therapeutics N.V. (PRQR)

NASDAQ: PRQR · Delayed Price · USD
0.626
-0.018 (-2.79%)
At close: May 25, 2022 4:00 PM
0.680
0.053 (8.525%)
Pre-market:May 26, 2022 4:28 AM EDT
Market Cap44.70M
Revenue (ttm)3.95M
Net Income (ttm)-69.73M
Shares Out71.36M
EPS (ttm)-0.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume493,986
Open0.644
Previous Close0.644
Day's Range0.612 - 0.657
52-Week Range0.530 - 9.090
Beta0.96
AnalystsBuy
Price Target10.49 (+1,574.6%)
Earnings DateMay 5, 2022

About PRQR

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Rad...

IndustryBiotechnology
IPO DateSep 18, 2014
CEODaniel De Boer
Employees181
Stock ExchangeNASDAQ
Ticker SymbolPRQR
Full Company Profile

Financial Performance

In 2021, PRQR's revenue was 2.40 million, a decrease of -74.64% compared to the previous year's 9.45 million. Losses were -61.62 million, 32.3% more than in 2020.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 14 analysts, the average rating for PRQR stock is "Buy." The 12-month stock price forecast is 10.49, which is an increase of 1,574.65% from the latest price.

Price Target
$10.49
(1,574.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDE...

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformat...

2 weeks ago - GlobeNewsWire

ProQR (PRQR) Reports Q1 Loss, Tops Revenue Estimates

ProQR (PRQR) delivered earnings and revenue surprises of 12% and 16.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

ProQR Announces First Quarter 2022 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

2 weeks ago - GlobeNewsWire

Bears are Losing Control Over ProQR (PRQR), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for ProQR (PRQR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, ...

3 weeks ago - Zacks Investment Research

ProQR (PRQR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision an...

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

4 weeks ago - GlobeNewsWire

ProQR to Participate in the Kempen Life Sciences Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

1 month ago - GlobeNewsWire

ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce

ProQR Therapeutics N.V. (NASDAQ: PRQR) has decided to prioritize the development of genetic eye disease candidates and the Axiomer RNA base-editing technology platform.

1 month ago - Benzinga

Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

1 month ago - PennyStocks

ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

1 month ago - GlobeNewsWire

ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

1 month ago - GlobeNewsWire

ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

2 months ago - GlobeNewsWire

ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates

ProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

3 months ago - GlobeNewsWire

Will ProQR (PRQR) Report Negative Q4 Earnings? What You Should Know

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Why ProQR Therapeutics Stock Got Slammed Again Monday

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.

3 months ago - The Motley Fool

ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study

ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.

3 months ago - Zacks Investment Research

Why ProQR Therapeutics Is Crashing Today

Sepofarsen's failure to meet efficacy endpoints in the Illuminate trial isn't sitting well with investors.

3 months ago - The Motley Fool

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

3 months ago - GlobeNewsWire

ProQR to Present at Upcoming SVB Leerink Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

3 months ago - GlobeNewsWire

Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength?

ProQR (PRQR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

3 months ago - Zacks Investment Research

ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

4 months ago - GlobeNewsWire

ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transformative RN...

4 months ago - GlobeNewsWire

ProQR Announces Highlights from Analyst Event

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

6 months ago - GlobeNewsWire

ProQR to Webcast Virtual Analyst Event on November 18

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transforma...

6 months ago - GlobeNewsWire